These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 30454829)

  • 1. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V; Morgan TR
    Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.
    Greuter T; Malhi H; Gores GJ; Shah VH
    JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences.
    Joshi-Barve S; Kirpich I; Cave MC; Marsano LS; McClain CJ
    Cell Mol Gastroenterol Hepatol; 2015 Jul; 1(4):356-367. PubMed ID: 28210688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
    Lai J; Wang HL; Zhang X; Wang H; Liu X
    Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
    Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
    J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic therapy: lessons from liver diseases.
    Garcia-Ruiz C; Marí M; Colell A; Morales A; Fernandez-Checa JC
    Curr Pharm Des; 2011 Dec; 17(35):3933-44. PubMed ID: 21933146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future therapy for non-alcoholic fatty liver disease.
    Issa D; Patel V; Sanyal AJ
    Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydroartemisinin alleviates steatosis and inflammation in nonalcoholic steatohepatitis by decreasing endoplasmic reticulum stress and oxidative stress.
    Li T; Chen Y; Tan P; Shi H; Huang Z; Cai T; Cheng Y; Du Y; Fu W
    Bioorg Chem; 2022 May; 122():105737. PubMed ID: 35338970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoplasmic Reticulum Stress Response in Non-alcoholic Steatohepatitis: The Possible Role of Physical Exercise.
    Passos E; Ascensão A; Martins MJ; Magalhães J
    Metabolism; 2015 Jul; 64(7):780-92. PubMed ID: 25838034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
    Jia Y; Ji P; French B; Tillman B; French SW
    Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis.
    Gentilini A; Caligiuri A; Provenzano A; Marra F
    Curr Mol Med; 2016; 16(8):710-720. PubMed ID: 27774883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways.
    Zhong X; Liu H
    Biomed Pharmacother; 2018 Feb; 98():111-117. PubMed ID: 29247950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.
    Musso G; Cassader M; Gambino R
    Nat Rev Drug Discov; 2016 Apr; 15(4):249-74. PubMed ID: 26794269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
    Pizarro M; Solís N; Quintero P; Barrera F; Cabrera D; Rojas-de Santiago P; Arab JP; Padilla O; Roa JC; Moshage H; Wree A; Inzaugarat E; Feldstein AE; Fardella CE; Baudrand R; Riquelme A; Arrese M
    Liver Int; 2015 Sep; 35(9):2129-38. PubMed ID: 25646700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
    Banini BA; Sanyal AJ
    Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.